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Introductory note and acknowledgements
In-depth reviews of topical interest are published as Selected issues each year. These reports are based on information 
provided to the EMCDDA by the EU Member States and candidate countries and Norway as part of the national reporting 
process.
The most recent Selected issues are:
•  Pregnancy, childcare and the family: key issues for Europe’s response to drugs;
•  Mortality related to drug use in Europe: public health implications;
•  Guidelines for the treatment of drug dependence: a European perspective;
•  Cost and financing of drug treatment services in Europe: an exploratory study;
•  Treatment and care for older drug users;
•  Problem amphetamine and methamphetamine use in Europe;
•  Trends in injecting drug use in Europe.
All Selected issues (in English) and summaries (in up to 23 languages) are available on the EMCDDA website:  
http://www.emcdda.europa.eu/publications/selected-issues
Links to online sources referred to in this publication are available in the PDF version, available at:  
http://www.emcdda.europa.eu/publications/selected-issues/prisons
The EMCDDA would like to thank the following for their help in producing this Selected issue:
•  the heads of Reitox national focal points, their staff and the national experts on drug-related deaths;
•  the services within each Member State that collected the raw data;
•  the members of the Management Board and the Scientific Committee of the EMCDDA;
•  the Publications Office of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is composed of national focal points in the EU 
Member States, Norway and the candidate countries and at the European Commission. Under the responsibility of their 
governments, the focal points are the national authorities providing drug information to the EMCDDA.




Over the last decade, Europe has seen an increase in the 
size of its prison population. As of 1 September 2010, there 
were an estimated 635 000 inmates in prison in EU 
Member States (Aebi and Del Grande, 2012; Walmsley, 
2012). Most of those in Europe’s prisons are from poor 
communities and vulnerable social groups (WHO Regional 
Office for Europe, 2007), with the proportion of inmates 
who are immigrants or from minority ethnic backgrounds on 
the increase (Ronco et al., 2011). Drug users form a large 
part of the overall prison population, with studies showing 
that a majority of prisoners have used illicit drugs at some 
point in their life and many have chronic and problematic 
drug use patterns. Because of the illegality of the drugs 
market and high cost of drug use, which is often funded by 
criminal activity, the more problematic forms of drug use are 
accompanied by an increased risk of imprisonment.
Although some prisoners do stop or reduce their use of 
drugs on prison entry, others initiate drug use or engage in 
more damaging behaviours when they are incarcerated 
(Lukasiewicz et al., 2007). In addition to high levels of drug 
Introduction
problems, prisoners also experience poorer health than the 
general population, with higher prevalence of blood-borne 
infections, such as human immunodeficiency virus (HIV) and 
hepatitis C virus (HCV), as well as mental illness. Reported 
rates of self-harm and suicide among prisoners are 
particularly high compared with the general population of 
the same age. In addition, overcrowding and poor hygienic 
conditions may further aggravate the stress, social and 
health problems experienced by prisoners. 
For opioid users, the risk of dying from drug overdose 
greatly increases in the period after release from prison 
— due to high rates of relapse and lower opioid tolerance 
(Farrell and Marsden, 2008). This is a critical time for 
action, when ensuring continuity of care and targeted 
interventions can both support recovery and save lives. The 
services offered to prisoners, however, have historically 
compared poorly with those provided in the community 
(Stöver and Weilandt, 2007). In general, services provided 
for prisoners have tended to mirror those provided in the 
community, but with a considerable time lag. Nevertheless, 
Sources of information on drug use 
and health responses in prisons
This Selected issue is based primarily on data provided by the 
Reitox network of national focal points, through either yearly 
routine reporting or a special data collection (1). The data 
available to the EMCDDA include both qualitative information 
on drug use and responses in prisons and quantitative data on 
prevalence and patterns of drug use among prisoners. In the 
absence of a common methodology for monitoring drug use in 
prison, the methods used across Europe vary, which limits the 
comparability of the data. The drug use statistics presented 
here are based mainly on studies carried out since 2006; 
however, owing to the scarcity of data, studies from as early as 
2000 have been included where more recent data are 
unavailable. Data from other EMCDDA sources are also used, 
among them data from the treatment demand indicator, which 
is applied in some countries in prison, and from the drug-
related infectious diseases indicator. Data on drug use in prison 
are presented in the 2012 Statistical bulletin. Additional 
information was obtained from the international scientific 
literature. 
A special data collection on health-related interventions for 
drug users in prison was conducted in 2011. This exercise 
collected information on healthcare priorities and levels of 
availability of selected measures through an expert survey 
among the 30 national focal points using a structured 
questionnaire. The respondents also provided a detailed report 
on the responses for drug-related health problems among 
prisoners in their country. 
Data on prison populations in Europe were obtained from the 
Council of Europe Annual penal statistics 2010 SPACE I by 
Marcelo Aebi and Natalia Del Grande. Data on prison 
numbers for other countries were obtained from the 
International Centre for Prison Studies’ World Prison Brief.
(1)  The 2010 Reitox national reports from 27 EU Member States, Croatia, 
Turkey and Norway are available on the EMCDDA website.
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Between 2001 and 2010, the prison population of the 27 
EU Member States increased from 582 000 to 635 000. 
Over that period, 18 of the 27 EU Member States and 
Norway reported increasing numbers of prisoners, a trend 
observed in most countries worldwide. The current EU prison 
population represents an average of 135 prisoners per 
100 000 population, with national figures ranging from 
60–70 per 100 000 population in Denmark, the 
Netherlands, Slovenia, Sweden and Norway to more than 
200 per 100 000 in the Czech Republic, Estonia, Latvia, 
Lithuania and Poland (Figure 1).
when appropriate drug services are in place, periods of 
incarceration may provide an opportunity for some to 
reduce their drug use and engage with treatment, and, in 
recent years, many European countries have increased the 
provision of services for drug users in prison, particularly 
substitution treatment. 
Recent years have also seen an increasing 
acknowledgement from international and European 
institutions of the importance of treating prison health as an 
inseparable component of public health. The Council 
Recommendation of 18 June 2003 and the 2009–12 EU 
action plan on drugs have both called for the development 
and implementation of prevention, harm reduction and 
treatment services in prison that are equivalent to services 
outside prison (1).
This Selected issue approaches the important topic of 
prisons and drugs in Europe from two perspectives. The first 
section aims to provide an insight into patterns and levels of 
drug use among the European prison population, the health 
profile of prisoners and risk behaviours while incarcerated. 
The second section examines Europe’s prison health policies 
and models of delivery of drug-related healthcare to 
detainees, including the provision of prevention, treatment 
and harm reduction services. The report concludes with 
reflections on ways forward.
The context: prisoners in Europe
In this Selected issue, the term ‘prisoner’ is used in a broad 
sense to mean anyone who is held in custody. This definition 
includes a range of legal statuses, from detainees who have 
not yet been tried to prisoners who are serving custodial 
sentences.
Less than 100
100 to less than 150
150 to less than 200
200 to less than 250
250 and over
 
Figure 1:  Prisoners per 100 000 population in EU Member States, 
candidate countries Croatia and Turkey and Norway in 
2010
Source: Council of Europe annual penal statistics: SPACE I — 2010.
(1)  Council Recommendation of 18 June 2003 on the prevention and reduction of health-related harm associated with drug dependence OJ L 165 13.7.2003, 
p. 31 and EU drugs action plan for 2009–12 OJ C 326 20.12.2008, p. 7.
9
Drug use among the prison population
Drug use, including problem drug use (2), is relatively 
common among the prison population. In the European 
Union, it has been estimated that about half of the prison 
population have used illicit drugs at some time in their lives 
(Zurhold et al., 2005). A systematic review of international 
studies — with a predominance of studies conducted in the 
United States — found that 10–48 % of men and 30–60 % 
of women were dependent on or used illicit drugs in the 
month before entering prison (Fazel et al., 2006).
Prisoners will have different experiences with drugs and 
crime. In Europe, offences related to the use, possession or 
supply of illicit drugs are the main reason for incarceration 
of between 10 % and 25 % of all sentenced prisoners (Aebi 
and Del Grande, 2011). Many, but not all, of these prisoners 
will have both experience of and problems with illicit drugs. 
Of those prisoners with a history of problematic drug use, 
some will have been imprisoned for a drug law offence, 
some for a crime committed to support their drug use (e.g. 
burglary, shoplifting) and some for offences unrelated to 
drugs.
Available data provide some insight into prisoners’ drug use 
before prison entry and their use of drugs during their 
period of imprisonment.
Experience of drug use among prisoners
Experience of illicit drugs is much more common among 
prisoners than among the general population. Among the 
17 European countries that have reported data on drug use 
among prisoners, the proportion of prisoners who have ever 
used any illicit drug before imprisonment ranges from 16 % 
in Romania to 79 % in England and Wales and the 
Netherlands, with nine countries reporting levels of use 
higher than 50 % (Figure 2). The variation between countries 
broadly reflects national levels of drug use, but may also 
partly reflect differences in data collection methods and 
practices.
Cannabis is the illicit drug with the highest reported level of 
lifetime prevalence among prisoners, with between 12 % 
and 70 % having tried it at some time in their lives. This 
reflects drug use experience in the general population, 
although the levels there are lower (1.6 % to 33 % among 
15- to 64-year-olds). Levels of use of cocaine, Europe’s 
second most commonly reported illicit drug, both inside and 
outside prison, are also much higher among prisoners 
(lifetime prevalence of 6–53 %) than among the general 
population (0.3–10 %). Experience of amphetamines among 
prisoners ranges from 1 % to 45 %, whereas among the 
general population the range is from almost zero to 12 %. 
Data on lifetime misuse of other substances (such as volatile 
substances, hypnotics and sedatives) are limited, and 
prevalence levels, among both prisoners and the general 
population, are usually low (EMCDDA, 2012).
Prisoners differ greatly from the general population in their 
reported experience of heroin. Whereas less than 1 % of the 
general population have ever used heroin, lifetime 
prevalence levels among European prisoners are much 
higher, with eight of the 13 countries that were able to 
provide information on heroin use reporting levels between 
15 % and 39 %.
(2)  The EMCDDA defines problem drug use as ‘injecting drug use or long-duration/regular use of opioids, cocaine and/or amphetamines’. See the problem 
drug use indicator on the EMCDDA website for more information.
Drug use and its consequences among the prison population
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and Ritter, 2008). For example, a Belgian study carried out 
in 2008 found that more than one-third of drug-using 
prisoners had started to use an additional drug during 
detention, one that they were not using before entering 
prison, with heroin being the drug most frequently 
mentioned (Todts et al., 2008).
Studies carried out in 15 European countries since 2000 
estimated that between 2 % and 56 % of prisoners have 
ever used any type of drug while incarcerated, with nine 
countries reporting levels in the range 20–40 % (3). The 
Drug use within prison
Imprisonment forces some drug users to stop using drugs, 
and some will see this as an opportunity to improve their 
lives. For others, however, prison may be a setting for 
initiation into drug use or for switching from one drug to 
another, often due to lack of availability of the preferred 
drug inside prison (Fazel et al., 2006; Stöver and Weilandt, 
2007) and other possible reasons (e.g. use of substances for 
which avoiding control measures is easier). Sometimes, this 
































































































































Figure 2:  Lifetime prevalence (%) of illicit drug use among prisoners in European countries
(1) Any of amphetamines, cannabis, crack, cocaine or heroin.
(2) Includes crack cocaine.
(3) Opioids.
NB:  Data refer to lifetime prevalence of use prior to imprisonment, with the exception of data for Belgium and Bulgaria, which refer to lifetime prevalence 
inside and outside prison. The prisoner sample in Finland was made up of convicts presenting for voluntary HIV testing; in the United Kingdom, the 
sample consisted of adults receiving sentences of between 1 month and 4 years. The studies were carried out in 2000 (Greece), 2001 (Finland), 
2003 (Italy, Lithuania, Netherlands), 2005/6 (United Kingdom), 2006 (Spain, Romania), 2007 (Poland, Portugal), 2008 (Slovenia), 2009 (Hungary) 
and 2010 (Belgium, Bulgaria, Czech Republic, Latvia, Croatia).
 For further information see Table DUP-1 in the 2012 Statistical bulletin.
Sources: Reitox national focal points.
(3) See Table DUP-1 in the 2012 Statistical bulletin.
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Imprisonment and drug use: 
the international picture
At an estimated 135 prisoners per 100 000 population, the 
level of incarceration in Europe is similar to that in Australia 
(134 per 100 000) and higher than that in Canada (117 
per 100 000). Considerably higher levels of imprisonment 
are reported in the United States (743 per 100 000 in 
2009) and Russia (590 per 100 000) (Aebi and Del 
Grande, 2011; Walmsley, 2012).
Outside Europe, data on drug use among prisoners mainly 
come from the United States, Australia and Canada. 
Despite the methodological differences in monitoring drug 
use in prison between different countries and world 
regions, data from all three countries show that the 
prevalence of drug use among prisoners prior to 
incarceration is substantially above the level in the general 
population. Comparing estimates of the more problematic 
forms of drug use between countries is hampered by the 
lack of an agreed international definition of the condition. 
The available European data indicate that one-third of 
prisoners show problematic drug-use patterns. In Canada, 
the percentage of prisoners diagnosed as having a 
substance abuse problem (70 %) is the nearest comparable 
measure, although this includes alcohol problems (CCSA, 
2012). In the United States, 65% of prisoners reportedly 
meet the criteria for substance use disorder under the 
Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition (CASA, 2010).
In Australia, two-thirds of all prison entrants reported using 
illicit drugs in the 12 months prior to prison entry. The most 
common illicit substances used by prisoners before 
incarceration were, in the following order: cannabis (51 %), 
methamphetamine (30 %), analgesics (16 %), tranquillisers 
(12 %), heroin (10 %) and ecstasy (10 %) (AIHW, 2011). 
Also in Australia, a recent study found that 36 % of 
prisoners reported the illicit use of pharmaceutical drugs 
such as buprenorphine, morphine, benzodiazepines or 
dexamphetamine at least once in the past 12 months (Ng 
and Macgregor, 2012).
There are also reports of high levels of experience of 
injecting drug use among prison populations outside 
Europe, with 34 % of Canadian drug offenders in prison 
and 55 % of Australian prison entrants reporting ever 
having injected a drug. Injecting while in prison is reported 
by 11 % of Canadian inmates.
drug most frequently used by prisoners is cannabis, followed 
by cocaine and heroin. Estimates of heroin use while in 
prison ranged from 1 % to 21 % of prisoners (4). The wide 
variation in prevalence levels between countries may reflect 
methodological differences in data collection and reporting. 
Factors such as price and availability will influence the 
substances used within prison, but studies suggest a 
tendency towards the use of depressant-type drugs such as 
heroin, hypnotics and sedatives or drugs with depressant 
effects such as cannabis. Stimulant drugs may be less 
popular, as the effects can be more difficult to manage, for 
both prisoners and prison staff, within the confined prison 
setting (Bullock, 2003).
Drug injecting and other health risk 
behaviours among prisoners
The close associations between injecting drug use and 
serious health risks, including blood-borne infections and 
overdose, have led to research into drug use patterns 
among prison populations focusing largely on drug 
injecting. 
Lifetime prevalence of injecting drug use is substantially 
higher among prisoners than among the general population. 
European countries report that between 2 % and 38 % of 
prisoners have ever injected heroin or other drugs prior to 
imprisonment. The most robust overall figure for drug 
injection among the European general population refers to 
those currently injecting, who are estimated to represent 
about 0.3 % of the adult population of the European Union.
In studies carried out in Europe since 2000, estimates of the 
prevalence of ever injecting illicit drugs while in prison 
range from 2 % to 31 % (Table 1). Data, however, are 
available for only a few countries, and differences in 
methodology mean that caution is required when comparing 
countries. The findings of qualitative studies suggest that in 
prison settings the likelihood of injecting in order to 
maximise the effect of the substance could increase, owing 
to the scarcity of drugs (EMCDDA, 2010b; Pena-Orellana et 
al., 2011). In addition, the scarcity of sterile equipment may 
lead to prisoners sharing syringes and other injecting 
paraphernalia, which increases the risk of infections.
(4) See Table DUP-3 in the 2012 Statistical bulletin.
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Additional risk factors for blood-borne infections include 
consensual and non-consensual unprotected sexual activity, 
including sexual assault and rape, which are reported to 
occur frequently in prison. In a large study conducted in 
Luxembourg in 1998, 90 % of the prisoners who reported 
having had sex in prison did not use condoms (Schlink, 
1999); in a recent study, the corresponding proportion was 
40 % (Origer and Removille, 2007). A number of other 
practices that are relatively frequent in prison are 
associated with increased risk of spread of infectious 
disease, including the sharing or re-use of tattooing and 
body-piercing equipment, sharing of razors, blood-
sharing/‘brotherhood’ rituals and the re-use or inadequate 
sterilisation of medical or dental instruments. In addition, 
inmates’ vulnerability to HIV and other infections may be 
indirectly increased by factors related to prison 
infrastructure and management, including overcrowding, 
violence and inadequate medical and social services 
(Jurgens et al., 2011; Rotily et al., 2001).
Social and demographic characteristics 
of drug treatment clients in prison
Information on the social characteristics of prisoners with 
drug problems is scarce, both in the scientific literature and 
from routine data; it mainly comes from qualitative studies 
(Vandam, 2009). Data on those entering drug treatment 
while in prison may provide a source of information on the 
social and demographic characteristics of drug users in 
prison settings. However, as only a small number of 
countries collect these data, and coverage may be limited, it 
Table 1:  Lifetime prevalence of drug injecting   
before and during imprisonment, 
in selected European countries






Belgium 15.2  2.3 2010
Bulgaria (1)  7.3  2.7 2009/06 (2)
Czech Republic 22.1  8.4 2010
Germany 31.0 22.2 2007
Spain 25.7  3.1 2006
France  7.0  — 2003
Italy 30.4  — 2001–02
Latvia (1) 21.1  8.5 2010
Luxembourg  — 31.0 2005
Hungary 10.4  0.7 2008
Poland (3)  5.9  3.3 2001
Portugal 12.6  1.9 2007
Romania  6.0  — 2006
United Kingdom  
(England) (4) 37.8  6.9 2004–05
United Kingdom
(England and Wales)  —  1.0 2001–02
United Kingdom 
(Scotland)  —  7.5 2009
Croatia  2.5  — 2010
(1) Heroin.
(2)  Data for injecting prior to imprisonment refer to 2009, data for 
injecting during imprisonment are from 2006.
(3) Adult males.
(4) Female prisoners.
Sources: Reitox national focal points.
Prison experience among problem drug users 
Studies among problem drug users show that many have 
spent time in prison, with between one-third and three-
quarters of different samples of users of opioids, cocaine 
and amphetamines and injecting drug users having ever 
been in prison. Among problem drug users, evidence from 
a Norwegian study suggests that males are more likely 
than females to have been imprisoned at some time, and 
that males serve longer sentences (Ravndal and 
Amundsen, 2010).
Problem drug use and drug dependence will increase the 
risk of imprisonment, due to the illegality of the drugs 
market and high cost of drug use, which is often funded by 
criminal activity. In addition, studies suggest that 
incarceration has an additional negative impact on these 
already vulnerable populations. Imprisonment is, for 
example, associated with higher rates of heroin or cocaine 
use, both in prison and outside prison (Gaffney et al., 
2008), increased benzodiazepine use in injecting drug 
users (McIlwraith et al., 2012), and earlier relapse after 
inpatient treatment (Smyth et al., 2010).
In light of the large overlap that exists between prison and 
problem drug use populations, prison samples (and 
criminal justice-involved samples, in general) are an 
important source of data for understanding the 
characteristics and estimating the size of populations of 
problem drug users, as they offer an opportunity to reach 
problem drug users who might never, or only much later, 
contact drug treatment services. Comparing their 
characteristics with treated clients gives a better 
understanding of treatment needs that are as yet unmet by 
existing services.
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must be borne in mind that this dataset can describe only a 
subset of drug users receiving treatment in prison settings.
Data on drug users entering treatment in prison show that, 
prior to incarceration, they have experienced generally 
poor social conditions, with many of them having a low 
level of educational attainment, while unemployment and 
living in unstable accommodation are also common. 
Furthermore, violence, abuse and poverty feature in the 
history of many prisoners who have used or are using drugs 
(Ronco et al., 2011).
Eight countries were able to provide information on 
prisoners entering drug treatment in 2010 (Germany, 
Ireland, France, Luxembourg, Hungary, Romania, Slovakia 
and Sweden, with a total of 5 146 prisoners). In these 
countries, the social profile of drug clients entering 
treatment in prison, while being generally similar to that of 
those entering treatment in the community, had some 
distinct characteristics. Men accounted for a greater share 
of those entering treatment in prison (around 90 %) than in 
community settings (80 %). And, while the average age of 
treatment clients was similar in the two settings (29 years in 
prison and 30 years in the community), prisoners reported 
an earlier age of first use of the primary drug for which 
they were receiving treatment (18 years compared with 21 
years among non-prisoners). Overall, heroin use was 
frequently the main reason for entering treatment in prison, 
although other primary drugs were reported by high 
proportions of prisoners entering treatment in several 
countries.
Health of drug-using prisoners
The health needs of prisoners are diverse and complex. 
Prisoners suffer from high levels of physical and psychiatric 
disorders, ranging from infectious diseases (HIV/AIDS, 
hepatitis B and C, tuberculosis) to psychiatric co-morbidity 
(antisocial and borderline personality disorder, depression, 
post-traumatic stress disorder, psychosis and alcohol 
dependence) (ECDC, 2010). 
Prison conditions may also have a detrimental impact on 
prisoners’ health. Overcrowding, in particular, is linked with 
increased stress and tension (Rouillon et al., 2007). In 15 out 
of 30 European countries (27 EU Member States, Croatia, 
Turkey and Norway) the occupancy rate in prison is over 
100 %, ranging from 102 % in Ireland to 153 % in Italy, 
according to the latest statistics from the Council of Europe 
(Aebi and Del Grande, 2012). In addition, the poor and 
unsanitary detention conditions in some prisons are likely to 
impact on the health of prisoners (WHO Regional Office for 
Europe, 2007).
Differences in morbidity between the prison population and 
the general population are shown by several studies, with 
prisoners more often presenting a problematic mental health 
profile (Fazel and Danesh, 2002). Compared with the 
general population, prison inmates experience poorer 
physical and mental health and social well-being, including 
both acute and long-standing physical and mental illness and 
disability, sexual health problems, suicide, self-harm, physical, 
psychological and sexual violence, lower life expectancy and 
breakdowns in family and other relationships, drug, alcohol 
and tobacco dependency (Barry, 2010).
According to recent European and international studies 
more than one-third of prisoners had an alcohol problem 
Health needs of female drug users in prison
On a given day more than 30 000 women are imprisoned 
in Europe, where they account for about 5 % of the prison 
population. Between 2000 and 2010, the number of 
women in prison grew by 27 %, and women’s share of the 
prison population also rose. Part of the increase may be 
due to women drug couriers, many of whom have been 
coerced into carrying drugs. In the United Kingdom, for 
example, female foreign nationals represented 19 % of the 
female prison population, with 80 % of them convicted of 
drugs offences (Corston Report, 2007). These women form 
a group with special needs. 
Women prisoners are more likely than their male 
counterparts to have been incarcerated for drug offences 
(Borrill et al., 2003) and to have serious drug-related health 
problems (Fazel et al., 2006), including infectious diseases 
(UNODC, 2008c). Female prisoners have specific 
treatment needs that are interwoven with their drug use 
history and drug-related lifestyles: many have experienced 
trauma related to physical and sexual abuse and violence 
and have to deal with mental health co-morbidities (WHO 
Regional Office for Europe, 2009). In addition, the risk of 
drug-related death is particularly acute among newly 
released women (Farrell and Marsden, 2008).
Responding to the requirements of women is challenging 
for prison authorities, because facilities and programmes 
are not typically developed to meet the specific 
psychological, social and healthcare needs of this small 
minority of inmates. Making sure that women have access 
to integrated treatment that addresses mental and somatic 
co-morbidities as well as drug dependence has been 
recommended (WHO Regional Office for Europe, 2009) 
alongside the systematic preparation of women prisoners 
for release, throughcare to drug treatment in the community 
and support to re-establish social support networks and 
family relationships (UNODC, 2008b).
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in the last year before entering prison (Lukasiewicz et al., 
2007), and almost 80 % smoked tobacco prior to arrest, 
compared with around 20–30 % in the general 
population (Hayton and Boyington, 2006; Kauffman et 
al., 2011).
Infectious diseases among injecting 
drug users in prison
HIV and hepatitis C virus
European data on HIV infection among injecting drug users 
in prison, albeit limited, show that the prevalence of 
infection varies, and in some countries it can be high 
among prisoners who have ever injected. Among the five 
countries providing data on HIV infection among injecting 
drug users in prisons between 2005 and 2010, HIV 
prevalence ranged from zero to 7.7 % in four countries 
while Spain reported a prevalence of 39.7 %. Reports from 
European countries with a high prevalence of HIV among 
injectors outside prison suggest that HIV prevalence is also 
high among injectors in prison. As higher proportions of 
prisoners inject or have injected drugs, the prevalence of 
HIV in prison populations can be much higher than that in 
the general population (5).
Data on hepatitis C virus (HCV) antibody prevalence among 
injecting drug users in prison between 2005 and 2010 were 
reported by five countries, with prevalence ranging from 
11.5 % (Hungary) to 90.7 % (Luxembourg). 
An analysis of studies undertaken in the community and 
reported to the EMCDDA, mostly in drug treatment and 
low-threshold services, assessed whether HIV prevalence 
differs by prison history of injecting drug users. Data since 
2005 from 15 European countries were analysed. HIV 
prevalence among injecting drug users who reported ever 
having been in prison (5.6 %) was about twice that among 
injectors who reported never having been in prison 
(2.6 %). A similar pattern was found for HCV infection, 
with a prevalence of 63 % among injecting drug users 
who reported having ever been in prison and 43 % 
among those who reported that they had never been in 
prison. The increased risk of HCV infection varied from 1.1 
times in Greece to 7 in Sweden and 19 times higher risk in 
Cyprus. Overall, the data suggest that, for injecting drug 
users in most countries, a history of imprisonment is 
associated with a two- to threefold increase in the risk of 
HCV infection, while in France, Cyprus and Sweden the 
increase is higher.
Tuberculosis
Prisons play a key role in the epidemiology of tuberculosis in 
Europe. The disease is more common among marginalised 
sections of the population, including those with drug 
problems, than in the community at large, and prevalence 
rates in European prisons usually far exceed those in the 
general population (Aerts et al., 2006). A recent systematic 
review indicates that the risk of acquiring tuberculosis is at 
least ten times higher in prisons than in the general 
population (Baussano et al., 2010). Conditions such as 
overcrowding and poor ventilation facilitate the transmission 
of tuberculosis among the prison population. Similarly, 
through infected visitors, prison staff and released prisoners, 
tuberculosis may be transmitted into the community. 
Psychiatric co-morbidity
Psychiatric co-morbidity is the co-occurrence of two or more 
mental disorders, usually a mental health and substance use 
disorder, in the same person. It particularly affects 
vulnerable groups, including problem drug users and prison 
populations, which are, to a large extent, overlapping. 
Studies have estimated that for several types of mental 
health disorders, including psychosis, personality disorders, 
anxiety and depression, co-morbidity occurs at substantially 
higher prevalence rates among prisoners than in the general 
population (Fazel and Baillargeon, 2011). 
A systematic review of 62 surveys covering about 23 000 
prisoners from 12 countries worldwide showed that up to 
65 % of prisoners have a mental health disorder, which may 
range from personality disorder (42–65 %, mostly antisocial 
disorder), to major depression (10–12 %) to psychotic 
illnesses (4 %; including schizophrenia, schizophreniform 
disorder, maniac episodes and delusional disorder). Those 
disorders represent a serious risk factor for suicide, which is 
the leading cause of death among those who are 
imprisoned (Fazel and Danesh, 2002).
Studies from European countries, including Spain, France 
and the United Kingdom, support those results (Birchard, 
2001). Particular attention has been drawn to personality 
disorders, which are often associated with problem drug use 
(Arroyo and Ortega, 2012). In a French study, the most 
common problems among prisoners with a diagnosis of 
psychiatric co-morbidity were depressive syndromes (40 %), 
generalised anxiety (33 %), traumatic neuroses (20 %), 
agoraphobia (17 %), schizophrenia (7 %), and paranoia or 
chronic hallucinatory psychoses (7 %) (Rouillon et al., 2007). 
(5) See Table INF-1 in the 2012 Statistical bulletin.
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Mortality among prisoners using drugs
Mortality among prisoners in general is high (30.6 per 
10 000 per year), according to a study of suicide and 
mortality in prisoners, using supranational data from the 
Council of Europe Annual Penal Statistics (SPACE) from 
1997 to 2008. Suicide is the leading cause of death in 
prison and accounts for around one-third of all prison 
deaths. In Europe, the risk of suicide among prisoners (10.5 
per 10 000 in prison) is estimated to be seven times that of 
the general population (EU average of 1.5 per 10 000 
population) (Rabe, 2012).
Drug-using prisoners represent a sizeable proportion of the 
prison population, and, while the evidence is not conclusive, 
it is likely that drug users represent a considerable share of 
the suicides in prison. Meta-analysis of studies suggests that, 
among other factors, drug problems might be a risk factor 
for committing suicide in prison (Fazel et al., 2011; Laishes, 
1997). And studies show that, in the community, drug users 
are more likely than the general population to commit 
suicide (Darke and Ross, 2002). 
In England, a study on 172 prison suicides in 1999–2000 
found that the most common methods of suicide were 
hanging and strangulation, using bed clothes and window 
bars (92 %), and only 3 % of the victims died of self-
poisoning (overdose). Drug-dependent prisoners who 
committed suicide did it early, and were twice as likely as 
other prisoners to commit suicide in the first week of 
detention. For all inmates, the authors identified the days 
following reception into prison as the period when suicide 
prevention measures are most needed, and that, in this 
respect, drug-dependent prisoners should be identified as a 
high-risk population and targeted by prevention measures 
(Shaw et al., 2004).
Mortality after prison release
Release from prison is a time associated with increased 
mortality from all causes and, in particular, from drug 
overdose. This risk does not appear to have decreased in 
the last 20 years (WHO Regional Office for Europe, 2010). 
During the period following release from prison and return 
to the community, prisoners face a range of physical, 
practical and psychosocial challenges (Binswanger et al., 
2011). For prisoners with a history of problematic drug use, 
this is a time of very high overdose risk, as a result of 
reduced tolerance to opioids and frequent relapse into 
heroin use. A review of drug-related deaths that occurred 
shortly after release from prison in Europe, Australia and 
the United States showed that six out of 10 deaths in the 
first 12 weeks after release were drug-related (Merrall et 
al., 2010). The authors concluded that there is an 
increased risk of drug-related death during the first two 
weeks after release from prison, and that the risk remains 
elevated up to at least the fourth week. A study in England 
and Wales also reported that six out of 10 deaths in the 
first two weeks after release were drug-related and that the 
risk of death was greatly elevated during the first two 
weeks following release from prison. During the first week 
after release, compared with the general population of the 
same age and sex, female prisoners were 69 times more 
likely to die of drug-related causes and male prisoners 28 
times more likely (Farrell and Marsden, 2008). In addition, 
an Irish study of drug users who died after prison release 
between 1998 and 2005 showed a considerable risk of 
death at the time of release. Among the 105 deaths 
identified, 28 % occurred within the first week of release 
from prison and a further 18 % in the first month (Lyons et 
al., 2010).
Mandatory drug testing in prison
The main purpose of mandatory drug testing is to prevent 
inmates from consuming drugs inside prisons and to identify 
those who require treatment. The information obtained can 
also be used to estimate the level of use and the types of 
drugs being used in prisons (Stöver et al., 2008).
Mandatory drug testing in prisons was first established in a 
number of European countries in the 1990s (MacDonald, 
1997), and is now carried out in most EU Member States. 
Urinalysis is the prevailing method employed, although 
countries report various methods and objectives of drug 
testing. Other types of biological samples are analysed, 
such as blood and oral fluids, hair follicles and sweat 
(Hoffmann, 2009). In addition to random testing, in some 
European countries inmates may also be tested upon 
prison admission, on suspicion of use, and before they 
leave the prison.
There are a number of problems associated with drug 
testing in prisons including cost, increased tension among 
prisoners, and negative impact on treatment compliance 
and effectiveness (Stöver et al., 2008). Studies have also 
reported links between testing and increases in harm. Drug 
testing is more likely to identify cannabis users, since 
metabolites of tetrahydrocannabinol, the main psychoactive 
chemical in cannabis, have a longer duration in the body 
than those of cocaine and heroin. This could lead would-be 
cannabis users to switch to ‘harder’ drugs. However, there 
is insufficient evidence to generalise these findings, and 
more research is needed to establish the efficacy of 
mandatory drug testing in prison (Bird, 2005).
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Responding to the drug-related healthcare needs of 
prisoners has been identified as a public health priority by 
the European Union and Member States. This is evident in 
the EU drugs action plan 2009–12, which sets for Member 
States the objective of providing drug users in prison with 
improved access to healthcare, in order to prevent and 
reduce health-related harm associated with drug 
dependence. It is also expressed in the Dublin Declaration 
on Partnership to fight HIV/AIDS in Europe and Central 
Asia, which identifies prisoners as a vulnerable population 
and sets time-bound targets for national governments to 
provide comprehensive HIV/AIDS services for them 
(ECDC, 2010). 
A number of recommendations and resolutions that address 
the broader topic of prison health have been adopted by 
the Council of Europe, through its Council for Penological 
Cooperation under the Committee of Ministers (6), including 
the European Prison Rules (7). In addition, guidance 
translating internationally recommended health standards 
into the prison setting and promoting evidence-based 
health interventions in prisons has been issued, including 
the World Health Organization’s (2007) health in prisons 
guide and the United Nations Office on Drugs and Crime’s 
(2012) briefing on HIV prevention, treatment and care in 
prisons.
To set the context for the care for drug-related problems in 
prison, this section first examines the administration of prison 
healthcare in European countries, and reviews national 
policies. This is followed by an overview of the available 
information on drug-related service provision in Europe, 
from prison entry to prison release, addressing counselling, 
treatment of drug dependence and the prevention of 
infectious diseases. 
Responding to drug-related healthcare needs in prison
The rights of prisoners in the European Union
In response to concerns about increasing prison 
populations, including overcrowding and rising numbers of 
foreign nationals in European prisons, in 2004, the 
European Parliament adopted a recommendation on the 
rights of prisoners in the European Union (a), which refers to 
the EU legal instruments dealing with the protection of 
human rights (b), treatment of drug users in prison (c) and 
reduction of health-related harm (d), as well as to the 
corresponding instruments adopted by the Council of 
Europe and the United Nations. The Parliament 
recommended the drafting of a binding prisons charter for 
Europe as well as the revision of the 1987 European Prison 
Rules (e), in order to incorporate a higher degree of 
protection. In the context of the adoption in 2008 of an EU 
framework decision (f) implying the option of a transfer of a 
sentenced prisoner to serve the remainder of the sentence 
in another Member State, growing importance is now 
being attached to ensuring common minimum prison 
standards across the EU Member States and to the 
exchange of best practices.
(a)  European Parliament recommendation to the Council on the rights of 
prisoners in the European Union (2003/2188(INI)) — document P5_
TA(2004)0142 (available online).
(b)  The Treaty on European Union and the Charter of Fundamental Rights 
of the European Union (available online).
(c)  Council Resolution on the treatment of drug abusers in prison, 
adopted at the meeting of the Justice and Home Affairs Council on 
27–28 February 2003 (available online).
(d)  Council Recommendation of 18 June 2003 on the prevention and 
reduction of health-related harm associated with drug dependence, 
OJ L 165, 3.7.2003, p. 31 (available online).
(e)  Recommendation Rec(87)3E of the Committee of Ministers on the 
European Prison Rules (available online).
(f)  Council Framework Decision 2008/909/JHA of 27 November 2008 
on the application of the principle of mutual recognition to judgments 
in criminal matters imposing custodial sentences or measures 
involving deprivation of liberty for the purpose of their enforcement in 
the European Union (available online).
(6) A compendium of the work of the Council of Europe published in 2007 is available online.
(7) See the box ‘Prison health standards in Europe: the European Prison Rules’. 
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Responsibility for prison health 
in European countries 
In Europe, the responsibility for the provision of healthcare in 
prisons has historically lain with the same ministry that is in 
charge of the overall management of prison services — 
generally the justice or interior ministries. In practice, this 
means that decisions about prison health are taken by the 
national prison administrations or specialised executive 
agencies such as the Criminal Sanctions Agency in Finland, 
the Custodial Institutions Agency in the Netherlands or the 
Irish Prison Service. In several countries, namely Belgium, 
Germany, Malta, Portugal, Finland and Norway, prison 
health policies are dealt with at regional or prison levels.
Seven countries, accounting for 40 % of all prisoners in the 
European Union and Norway (8), have transferred or are in 
the process of transferring competence for delivering 
prisoner healthcare to the same structures that provide 
healthcare in the community. An important rationale for this 
change has been the need to integrate prison health 
structures with those in the community and improve the 
continuity of care for prisoners. In some countries, the move 
followed recognition of the need to tackle prison health 
problems more effectively, and to improve the quality of 
care for prisoners through easier access to medical 
specialists from public health structures. In some countries, 
such as Sweden and the United Kingdom, this move seems 
to have been accompanied by increased funding to engage 
prisoners in drug treatment programmes.
Among EU Member States, Sweden has the longest 
experience of involving the Ministry of Health in prisons, 
with a law from the early 1980s (Bill 1982/83:85) 
stipulating that general health services should care for 
prisoners just as they care for other citizens. However, while 
the Ministry of Health funds the medical treatment of 
inmates, prison healthcare units are run by the Swedish 
Prison and Probation Service under the Ministry of Justice, 
which is also in charge of providing cognitive treatment and 
educational activities targeting imprisoned drug users.
In Norway, since 1988, municipal health services have been 
responsible for the provision of primary healthcare to the 
inmates of prisons located in their area. As the Norwegian 
prison system consists of many small prisons, this solution 
offers practical advantages, including better availability of 
healthcare. Steps are currently being taken towards a further 
integration of service provision, in particular the 
incorporation of specialised drugs care and rehabilitation 
competence in prisons.
In France, since 1994, prison healthcare has been provided 
through the public hospital system. Each prison has an 
agreement with a public hospital, which is responsible for 
the healthcare of the inmates. Addiction treatment costs are 
covered by French social security, and contributions for 
inmates to the scheme are paid by the Ministry of Justice. 
Between 2003 and 2006, responsibility for commissioning 
and funding healthcare in public prisons in England and 
Wales was transferred from the prison administrations to 
public healthcare providers. The change was accompanied 
by an increase in funding of 78 % in England and 30 % in 
Wales. In Northern Ireland, the South Eastern Health and 
(8) Spain, France, Italy, Slovenia, Sweden, United Kingdom and Norway.
Prison health standards in Europe: 
the European Prison Rules
European and international prison rules (1) promote 
equivalence of care between prison and community and 
provide guidance on the organisation of imprisonment, 
including preparation for release as well as prison 
inspection and monitoring. The standards set by these rules 
provide a frame of reference for the judgments of the 
European Court of Human Rights, and are a benchmark 
against which conditions of detention are evaluated in 
Member States. 
The European Prison Rules include a set of 
recommendations on the organisation and provision of 
healthcare and on the qualifications and duties of the 
medical staff. The principles stipulated in the Prison Rules 
apply equally to the provision of healthcare for problems 
related to drug use. Under the ‘principle of equivalence’, 
prisoners shall have access to the health services available 
in the country, without discrimination on the grounds of 
their legal situation; the prison health staff shall have 
adequate training and be able to identify mental health 
problems; and those in need of specialised treatment not 
available in prison shall be transferred to external 
institutions.
(1)  Standard Minimum Rules for the Treatment of Prisoners (SMRTP), 
adopted by the First United Nations Congress on the Prevention of 
Crime and the Treatment of Offenders, held at Geneva in 1955, and 
approved by the Economic and Social Council by its resolutions 663 
C (XXIV) of 31 July 1957 and 2076 (LXII) of 13 May 1977 (available 
online) and Recommendation Rec(2006)2 of the Committee of 
Ministers to Member States on the European Prison Rules (available 
online). The European Prison Rules follow the general lines of the 
SMRTP, which set out consensual principles and practices in the 
treatment of prisoners, covering accommodation, hygiene, food, 
exercise and medical services.
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Social Care Trust took charge of prison health in 2008, and, 
in Scotland, the transfer to the National Health Service took 
place in 2011. 
In Spain, the management of all prison healthcare units, the 
planning of drug policies, epidemiological surveillance and 
the prison health information systems are coordinated under 
the secretary general of Spanish prison institutions. Care is 
provided using an integrated model with shared funding 
from the Ministry of Interior for primary health services and 
from the Ministry of Health for external healthcare services 
delivered by non-governmental agencies. All prison 
healthcare personnel are currently being transferred from 
the national Ministry of Interior to the health structures of the 
Autonomous Communities. 
In Italy, the Ministry of Health has been responsible for 
prison health since 2008, and all health units in prisons 
operate under its authority. In Slovenia, regional health 
centres became responsible for prisoner healthcare in 2009, 
when prison health was integrated in the public healthcare 
system.
Drug-related prison health policies
Drug-related health issues in prisons have been an important 
focus for European policymakers in recent years. Two 
reports issued by the European Commission in 2007 (9) and 
2008 (Stöver et al., 2008) highlighted the lack of available 
services for drug users in prisons and drew attention to the 
importance of intervening in this setting. As noted earlier, 
improved provision of healthcare for drug users in prison 
has been an objective in the 2009–12 action plan on drugs, 
and 15 EU Member States, as well as Croatia and Norway, 
specifically address drug-related prison health in their 
national drug policies. 
Furthermore, in 10 EU Member States, drug-related prison 
health is covered in a national prison health strategy, in a 
strategy dedicated specifically to drug-related prison health, 
or in both.
There is evidence of increasing coordination and 
cooperation between agencies around prison health 
planning and service provision. An example of a recent 
multi-stakeholder prison health plan is the French strategy 
‘Santé/Prison’ for 2010–14, developed by the Ministry of 
Health and Sports in collaboration with the Ministry of 
Justice and Liberties and involving the National Institute for 
Prevention and Health Education (INPES), the National 
Institute for Public Health Surveillance (InVS) and the Agency 
for Shared Information Systems (ASIP Santé), as well as a 
general adviser for health establishments. This national 
strategic action plan for improving the health of detainees is 
consistent with the objectives of the French national action 
plan on drugs and drug addictions (2008–11) and 
emphasises the importance of continuity of care after 
release from prison, especially through the provision of 
housing. 
In England, since 2008, an integrated drug treatment system 
(IDTS) has been implemented in all adult prisons, with the 
aim of improving the coordination of planning and delivery 
of all drug treatment interventions, both clinical and 
psychosocial. The IDTS aims to improve collaboration 
between prisoners and the prison system through an 
individual treatment plan, and to ensure continuity with 
community treatment at both the start and finish of custody. 
Each prison has its own drug and alcohol strategy, and a 
review of this is carried out annually. Also in the United 
Kingdom, a prison drug treatment strategy review was 
carried out, under which an independent expert group 
assessed rehabilitation measures for drug users in prison 
and on release with regard to their effects on reducing 
drug-related crime and rehabilitating offenders, and came 
forward with recommendations for an evidence-based 
approach to prison drug treatment (Prison Drug Treatment 
Strategy Review Group, 2010).
In Portugal, the provision of healthcare, treatment and harm 
reduction measures is ensured through the use of 
collaboration procedures between the health and justice 
ministries.
In the majority of European countries, drug treatment in 
prisons is provided by staff employed by the prison 
administration. However, it is also common for prison 
administrations to collaborate with a range of community-
based providers, public health services or non-governmental 
organisations in order to deliver drug treatment services to 
those in detention. Collaboration can entail bringing in 
personnel from public services to work alongside prison staff 
or having external providers ‘reach in’ and work 
independently inside prison. In the Netherlands, mixed 
teams are the main providers of all types of drug treatment 
in prisons, and in the United Kingdom they are the main 
providers of opioid substitution treatment. In Greece, 
non-governmental organisations are the only provider of 
drug treatment in prisons. 
(9)  COM report on follow-up to Council Recommendation of 18 June 2003 on the prevention and reduction of health-related harm associated with drug 
dependence (available online).
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Provision of drug-related 
health services in prison
As a general principle, prisoners are entitled to the same 
level of medical care as persons living in the community, 
and prison health services should be able to provide 
drug-related treatment and care in conditions comparable to 
those enjoyed by patients outside (10). The following sections 
describe what drug-related health services are provided to 
prisoners on entry into custody, during imprisonment and 
upon release. 
Prison entry
Medical examination of all those remanded in custody or 
entering prison after conviction is a widely accepted 
standard of prison healthcare. The aim here is to diagnose 
any physical or mental illnesses that might be present and 
take the necessary treatment measures, such as ensuring the 
continuation of existing medical treatment. Although 
information from some countries is incomplete, a general 
picture emerges from the available data. The overall health 
condition of prisoners is screened by the prison doctor or 
nurse immediately at entry or within the first 24 hours and, 
in several countries, withdrawal symptoms are assessed and 
medication needs are established. 
This is followed by a comprehensive medical examination, 
which takes place in a specified time, which can vary 
depending on the country from ‘within the first working day’ 
to up to ‘within 20 working days’. This examination typically 
involves a thorough medical assessment (11), an evaluation of 
the need for specialist care and the testing for blood-borne 
viruses and sexually transmitted infections. 
Tests for infectious diseases should be offered but should not 
be mandatory (EMCDDA, 2010a). Information on specific 
screening policies was available from only a few countries. 
For example, in Romania, HIV screening requires written 
consent; however, if the prisoner tests positive, screening for 
sexually transmitted infections will also be performed. In 
Estonia, where tuberculosis affects more than 20 per 
100 000 inhabitants, and where an increase in tuberculosis 
patients carrying multidrug-resistant pathogens was detected 
in 2010, a more active tuberculosis screening is 
implemented based on the national tuberculosis prevention 
strategy (2008–12). During the medical examination on 
prison entry, in cases where it is required, a radiographic 
examination is performed. Testing for HIV and viral hepatitis 
B and C is done on a voluntary basis in all prisons and 
always includes pre- and post-test counselling. It is 
performed when an individual arrives in prison, one year 
after previous testing or, more frequently, where medical 
necessity demands. In Lithuania, since 2002, prisoners are 
required by law to comply with procedures for preventing 
dangerous and highly contagious infectious diseases.
In Hungarian prisons, voluntary testing for hepatitis B and C 
and HIV is conducted periodically — not on prison entry — 
as part of an extensive screening campaign taking place in 
prisons since 2007. In Germany, rules on testing vary 
between Länder, and no central dataset is available. 
In most countries, a confidential health record is created 
during the prison entry examination, which accompanies the 
prisoner throughout the time in prison. Electronic information 
systems and centralised databases are increasingly being 
used to maintain a centralised overview of prisoners’ health.
Assessment of drug problems
In a majority of countries, new inmates are routinely 
assessed for drug use and drug-related problems. Sixteen 
countries report procedures other than urine testing to detect 
illicit substances. The common approach is a clinical 
assessment carried out by a medical doctor, psychiatrist or 
psychologist in order to ascertain a diagnosis of drug 
dependence and mental health problems, but in some 
countries standardised tests, questionnaires and interviews 
are used for this purpose. In Sweden, all prisoners are 
classified by prison personnel with regard to level of 
addiction, with a follow-up Addiction Severity Index (12) 
interview when needed. In Scottish prisons, following a core 
screening, inmates with drug problems are referred for 
specialist substance misuse assessment. In England, CARATs 
teams (Counselling, Assessment, Referral, Advice and 
Throughcare services) carry out a brief substance use 
assessment and, if needed, triage. In Spain, Italy and the 
Netherlands, social workers and psychologists carry out a 
multidisciplinary assessment, evaluate psychological, social 
and legal areas and draw up an individual care plan. 
The medical consultation upon prison entry is also used as a 
first opportunity to inform prisoners about treatment and 
prevention, raise risk awareness, distribute prevention 
(10)  See also the box on the European Prison Rules, p. 17.
(11)  European Prison Rules — Part III: Health — Duties of the medical practitioner — Rule 43.2. Available online.
(12)  The Addiction Severity Index (ASI) is an assessment instrument, designed to be administered as a semi-structured interview, that gathers information about 
seven areas of a client’s life: medical, employment/support, drug and alcohol use, legal, family history, family/social relationships and psychiatric 
problems.
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materials, including hygiene kits and condoms, and make 
referrals to specialised drug treatment and care.
Assessment of suicide risk
The importance of early identification of drug-using 
prisoners at risk of suicide and referring them to adequate 
treatment was shown in England, where the implementation 
of an integrated treatment system in all prisons led to a 
dramatic reduction in suicides among the population of 
women prisoners, from a total of 36 in the preceding three 
full years (2002–04) to 15 in the three years following the 
start of the programme (2005–08) (Marteau et al., 2010).
Treatment of drug dependence
Treatment for drug dependence is aimed at both improving 
the health of detainees and reducing the often high levels of 
illicit drug use in prisons. Treatment options for drug users in 
European prisons cover a range of modalities, which, in the 
absence of a standard nomenclature, are broadly 
categorised into three types:
1.  ‘low-intensity drug treatment’, which covers counselling 
interventions as well as short-term treatment conducted in 
an outpatient regime within the prison setting; 
2.  ‘medium- or high-intensity drug-free treatment’, defined as 
including inpatient wards for the delivery of drug 
treatment in a residential setting, e.g. therapeutic 
communities in prison;
3.  ‘medium- or long-term opioid substitution treatment’, 
covering methadone or buprenorphine substitution 
programmes. 
The following sections summarise the available information 
and expert opinion about the provision of detoxification and 
drug treatment services in European prisons. 
Detoxification
In many countries, detoxification is still the ‘default’ treatment 
for the majority of opioid users entering prison. 
Detoxification policies vary between countries and can also 
differ between prisons in the same country. Withdrawal 
symptoms are usually evaluated by a doctor and 
pharmacologically supported. Some prisons are equipped 
with specific detoxification inpatient facilities for cases 
where hospitalisation is necessary. In countries with smaller 
prison systems, such as Luxembourg, detoxification may be 
provided in collaboration with a psychiatric hospital. 
Detoxification regimes vary in length and form, depending 
on the individual’s clinical condition. Medically assisted 
detoxification is available in all prisons in Ireland, and a 
specialist ward with capacity for nine prisoners is operating 
in the country’s largest institution, Mountjoy Prison. Here, a 
typical programme includes psychosocial counselling and 
lasts six weeks, which allows 70 prisoners per year to 
benefit from it. In contrast, detoxification in Turkish prisons 
mainly involves the provision of information on drug 
addiction, increasing inmates’ skills in managing withdrawal 
symptoms and craving, and training in relaxation methods. 
Low-intensity treatment including counselling (outpatient)
Some form of low-intensity drug treatment was reported to 
be available in prison systems in all countries except Cyprus. 
The measures reported by national focal points included 
psychological counselling, crisis intervention, needs 
assessment and care planning, motivational programmes or 
drug treatment of short duration aiming at drug use 
reduction, relapse prevention or harm reduction. Among the 
counselling and treatment approaches mentioned were 
motivational interviewing and cognitive–behavioural and 
socio-educational interventions (e.g. social skills training). 
Educational and information programmes were delivered in 
group sessions, whereas treatments were administered 
usually in individual consultations. 
The range of interventions reported was broad. In Slovakia, 
for example, programmes focus on psycho-education, sports 
activities and spiritual services; the Swedish Prison and 
Probation Service uses mainly cognitive–behavioural 
treatment programmes to address drug-using prisoners’ 
behavioural problems and reduce re-offending; and, in 
Bulgaria, the focus of a short-term programme delivered to 
prisoners in daily sessions over 20 days is the reduction of 
drug-related harm.
Reports suggest that interventions aimed at spreading 
general information on drug prevention and risks are 
common in European prisons. These are frequently delivered 
to prisoners in group settings. In 2010, nearly one-quarter of 
all prisoners in the Czech Republic received at least one 
intervention from drug prevention and counselling centres, 
while in the same year in Latvia, 4 000 counselling sessions 
and 1 700 individual consultations took place. Data from 
Lithuania document that 80 % of prisoners were reached in 
2010 with information about drug prevention, treatment and 
rehabilitation. 
Intensive and individualised counselling approaches are 
more targeted, and reach a smaller number of prisoners. In 
Slovenia, for example, 186 prisoners were involved in 
medium-threshold treatment programmes during 2010, while 
in Denmark 455 prisoners were reached by such 
programmes. Furthermore, the Irish Prison Service reported 
that addiction counselling services provided by 23 
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counsellors delivered approximately 1 500 prisoner contacts 
per month, and in Luxembourg, services provided to a total 
national prisoner population of 680 (on a given day) 
included 45 health prevention groups, 274 individual 
prevention interviews and 1 238 therapeutic counselling 
sessions. In Greece, drug treatment services for prisoners 
are provided by the non-governmental organisations 
KETHEA and ‘18 ANO’. In 2010, more than 1 800 drug-
related counselling sessions were delivered in 19 of the 32 
Greek prisons. 
As most countries do not possess reliable data on the 
prevalence of drug use and related treatment and 
counselling needs among prisoners, the Reitox national focal 
points were asked to assess current levels of treatment 
provision and give information on types of providers and 
models of service provision. Respondents were instructed to 
judge the treatment offer against the needs of drug users 
actively seeking treatment and to rank treatment providers 
according to the numbers of prisoners they reach.
Capacity for low-intensity treatment was considered as 
fully matching prisoners’ demand in nine countries, where 
nearly all prisoners in need would obtain it. In 10 other 
countries, provision was judged sufficiently extensive to 
enable a majority of prisoners in need to obtain such 
treatment. A lack of capacity was identified in Estonia, 
Greece, Latvia, Hungary and Romania. In prisons in 
Cyprus, low-intensity drug treatment programmes were not 
available in 2010 (13).
National experts reported that health services run by the 
prison system were the main providers of low-intensity 
treatment services in 19 countries (14). External providers 
were judged to make an important contribution in eight of 
the 25 countries that answered the question: community-
based public health services, non-governmental 
organisations that provide services through ‘in-reach’ or 
mixed teams of prison personnel and externally contracted 
staff were identified as main providers in Greece, Italy, the 
Netherlands, Slovenia and the United Kingdom, and were 
ranked on equal footing with prison health services as the 
main providers in Denmark, Malta and Croatia. In France, 
prison health services work under the authority of the public 
health system in partnership with a hospital. 
Medium- or high-intensity drug-free treatment (inpatient)
Abstinence-based residential drug treatment programmes 
have a long tradition in prisons. Such programmes operate 
in a similar manner to residential programmes in the 
community, providing group and individual treatments, and 
professional staff may be supported by treated prisoners. 
Various therapeutic models may be offered, including 
cognitive, behavioural and 12-step programmes. The 
UNODC Treatnet project describes the different types of 
residential drug-free treatment approaches available in 
prisons (UNODC, 2008a). These include cognitive–
behavioural treatment, in which structured psychological 
interventions help the prisoner to develop the skills 
necessary to stay drug free. Strategies include relapse 
prevention such as coping strategies, identification of 
high-risk situations and triggers to drug use, and identifying 
dysfunctional thinking patterns, managing emotions and 
problem solving.
Also used in prisons is the 12-step residential approach, 
based on the Alcoholics Anonymous model, which assumes 
a biological or psychological vulnerability to dependency. 
The treatment goal is abstinence, and prisoners usually work 
their way through the first five steps of the 12-step 
programme. Programme graduates will be expected to 
attend self-help groups in prison and in the community on 
release. 
Therapeutic communities are a special form of long-term, 
participative, group-based residential treatment of drug 
addiction, where milieu therapy principles are applied, 
meaning that clients are encouraged to take responsibility 
for themselves and for others. 
There is a lack of research and evaluation of prison-based 
treatment programmes and too little is known about their 
effectiveness. However, two randomised trials conducted in 
prisons were included in a review of the effectiveness of 
therapeutic communities versus other treatments for 
substance dependents (Smith et al., 2006). While the 
authors found little evidence that therapeutic communities 
offer significant benefits in comparison with other residential 
treatment provided in community settings, inmates of 
prison-based therapeutic communities were less likely to 
return to prison within the first 12 months after, compared 
with prison inmates receiving no treatment or assigned to 
alternative services. Thus, prison therapeutic communities 
may be better than prison on its own, but a number of 
methodological limitations are mentioned by the authors, 
preventing them from drawing firm conclusions. The fact that 
both trials were conducted in US prisons may limit the 
transferability of the results to Europe. 
(13)  Five countries (Belgium, Spain, France, Sweden, Turkey) provided no information.
(14)  No information was available from Belgium, Spain, Cyprus, Sweden, Norway and Turkey.
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Residential drug-free treatment is provided through 
therapeutic communities or special inpatient wards in 21 of 
the 25 countries that provided information (Figure 3). Cyprus 
established a drug-free treatment inpatient programme in 
2011. 
Drug-free inpatient treatment or therapeutic communities in 
prison was considered to be available to all or almost all of 
those who need it in four (Denmark, Lithuania, Luxembourg, 
Croatia) of the 21 countries that were able to provide 
information, and to a majority of prisoners in a further nine of 
these countries (Figure 3). This type of treatment was seen as 
available to more than a few but not a majority of prisoners 
in need in six countries, namely the Czech Republic, Estonia, 
Greece, Malta, Finland and Norway and restricted to just a 
few prisoners in Ireland, Latvia and Romania.
Four countries did not provide a rating of the provision of 
drug-free inpatient treatment in prisons, but gave some 
additional information in their national report, which allows 
the conclusion that such services exist in three of them. 
While in Spain these take the form of residential ‘treatment 
and educational units’ set up in 12 prisons, much of the 
Swedish inpatient service provision seems to follow the 
12-step Minnesota model. And with Belgium now also 
planning to start up a therapeutic community, the only 
country for which no information is available is Turkey.
Prison health services are the main provider of drug-free 
inpatient treatment in 16 countries, with external providers 
or mixed teams playing an equal role in Denmark and 
Malta, and a main role in Italy, Slovenia, the Netherlands 
and the United Kingdom.
Opioid substitution treatment
Substitution treatment is the main approach in the treatment 
of opioid dependence in the European Union and is 
implemented in all Member States, Croatia, Turkey and 
Norway. With around 710 000 opioid substitution 
treatments reported in 2010, it covers at least one in two of 
the estimated population of problem opioid users (EMCDDA, 
2012). Most European countries have introduced substitution 
treatment among the range of options for opioid-dependent 
prisoners, and the ‘treatment gap’ between community and 
prisons may now be closing, at least in some countries 
(Hedrich and Farrell, 2012). However, there has been a 
considerable delay in introducing opioid substitution 
treatment in prisons, which has generally occurred about 
eight to nine years after the treatment option was 
implemented in the community (see Figure 4).
A systematic review of the effectiveness of opioid 
maintenance treatment in prison (Hedrich et al., 2012) 
analysed data from 21 studies, including six experimental 
studies. The authors concluded that the benefits of the 
treatment in prison are similar to benefits in community 
settings; namely, it presents an opportunity to recruit 









Figure 3:  Estimated availability of residential drug-free treatment 
in European prisons
NB:  Availability is defined by the estimated proportion of drug users in 
need of treatment who can receive it: nearly all (full); the majority, 
but not nearly all (extensive); more than a few, but not the majority 
(limited); only a few (rare); not available. 











Figure 4:  Cumulative number of European countries that had 
officially launched opioid substitution treatment as a 
recognised method of treatment in community and 
prison settings
Sources: Reitox national focal points.
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use and risk behaviours in prison and potentially minimise 
overdose risks on release. Positive outcomes depended on 
the quality of treatment. The review highlights the 
importance of establishing a liaison between prison and 
community-based programmes in order to achieve 
continuity of treatment and longer-term benefits. The data 
also show that disruptions in the continuity of treatment, 
especially owing to short periods of detention, are 
associated with very significant increases in hepatitis C 
incidence.
In 2012, Greece, Cyprus, Lithuania and Slovakia are the 
only countries where prison doctors are not allowed to 
prescribe long-term substitution treatment (15). In Hungary, 
although the treatment has been officially allowed in prisons 
since in 2001, it was only implemented in a few isolated 
cases in the years 2005–06. In Turkey, an option to provide 
substitution treatment has been available in prisons since 
2010, but the availability of substitution maintenance 
treatment as compared with reduction programmes is not 
clear. In 2011, Latvia permitted opioid substitution treatment 
to be used in the long-term care of prisoners, extending the 
current model of reduction treatment to a maintenance 
approach. In all other countries, drug users who are 
receiving substitution treatment in the community can 
continue upon entry to prison. In addition, this treatment can 
also be initiated during the period of detention in most of the 
countries where continuation is possible, with the exception 
of the Czech Republic, Latvia, Poland and the United 
Kingdom (Northern Ireland).
In order to describe the level of implementation of opioid 
substitution treatment, in the absence of reliable data on 
the number of opioid-dependent prisoners, two 
complementary approaches have been followed. First, the 
proportion of prisoners receiving opioid substitution 
treatment was calculated (16). In addition, because this 
method does not differentiate between countries with high 
or low levels of problem opioid use, national focal points 
were asked to provide an expert rating on the level of 
provision in relation to the number of prisoners in need of 
treatment. The results of the two methods are in broad 
agreement (Table 2).
It is estimated that opioid substitution treatment is received 
by more than 10 % of all prisoners in seven EU Member 
States, and by between 3 % and 10 % in another nine 
countries. Compared with 2008 (17), provision has increased 
in most countries.
(15) See Table HSR-9 and Figure HSR-4 in the 2012 Statistical bulletin.
(16)  Two different methodologies were used and are described in Figure HSR-4 in the 2012 Statistical bulletin. See Table HSR-9 for information on the numbers 
of opioid substitution treatments reported.
(17) For 2008 data, see Figure HSR-4 in the 2010 Statistical bulletin.
Table 2:  Provision of substitution treatment in prison: comparison of expert ratings and the 
percentage of prisoners reported to be receiving substitution treatment
Expert rating on 
provision in 2010
Percentage of prisoners receiving opioid substitution treatment in 2010
Zero Less than 3 % 3 % or more, but  
less than 10 %
10 % or more
Full Estonia Denmark Ireland, Spain, Luxembourg, 
Austria, Slovenia, 
United Kingdom
Extensive Poland France, Netherlands, 
Portugal, Norway
Limited Czech Republic, Romania Italy, Croatia Malta
Rare Finland
Treatment not available Greece, Cyprus, Lithuania, 
Slovakia, Turkey
Expert rating not available Latvia, Hungary Bulgaria, Sweden Belgium, Germany
NB:  Availability is defined by the estimated proportion of drug users in need of treatment who can receive it: nearly all (full); the majority, but not nearly 
all (extensive); more than a few, but not the majority (limited); only a few (rare); not available.
Sources: Reitox national focal points.
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Prevention of drug-related infectious 
diseases in prison settings
Prisoners are at great risk of contracting infectious diseases: 
they are exposed to an often overcrowded environment with 
higher levels of disease prevalence and fewer options to 
protect themselves from infections than they would have 
outside (Laticevschi, 2007). By providing inadequate 
healthcare for inmates with communicable diseases, prisons 
may place at risk both other inmates and the public (APHA 
Task Force on Correctional Health, 2003). 
A solid evidence base exists for a number of cost-effective 
public health interventions to reduce and control infections 
among drug users (ECDC and EMCDDA, 2011). These 
include testing, vaccination and treatment of infections, as 
well as interventions aiming at the reduction of drug use and 
injecting-related risk behaviour, ranging from health 
promotion and drug dependence treatment to needle and 
syringe programmes.
The survey among national focal points sought to identify 
national priorities in the prevention of infectious diseases 
among drug users in prison settings (18). Twenty-five countries 
answered the question, and the most commonly identified 
priority measures were hepatitis vaccination programmes 
and voluntary infectious disease counselling and testing on 
prison entry (Figure 5). Furthermore, drug treatment was 
identified as a priority for preventing infectious diseases in 
prison settings: 10 countries prioritised drug-free treatment in 
specialised prison treatment wards or prison therapeutic 
communities, eight of which also identified the option of 
initiating opioid substitution treatment in prisons or of 
placing prisoners in medium- or long-term opioid substitution 
programmes as a strategic priority. One or both opioid 
substitution measures were identified as a priority in 15 of 
the 25 countries. Counselling, individual risk assessments 
and the dissemination of information materials about 
infectious disease prevention were less often identified as 
priority interventions. 
Survey respondents were asked to judge the extent to which 
the availability of selected prison interventions matched the 
demand in their country. The results indicate that testing for 
hepatitis C on prison entry was available to a majority or 
nearly all of those who need it in 17 countries. 
Hepatitis B vaccination programmes in prison exist in 16 of 
the 26 countries that were able to provide information, and 
drug users are their main target group. Some countries 
report specific accelerated schedules, others the general use 
of the combined hepatitis A and B vaccine. Data on the 
uptake of such vaccinations are, however, extremely scarce. 
In Scotland, hepatitis B vaccination has been offered to all 
prisoners within 24 hours of admission since 1999, and, 
since 2000, all prisoners diagnosed with HCV infection 
have been offered the hepatitis A vaccine. Since 2009, both 
vaccines are routinely offered to all drug-using prisoners on 
admission. 
Survey respondents perceived the availability of individual 
counselling on drug-related risk behaviour as either rare or 
limited in 13 countries, while such counselling was seen as 
being available to a majority or nearly all of those who 
need it in 11 countries. Safer drug use training was offered 
in prisons in 12 countries, but availability was mainly 
perceived as limited or rare (10 countries). Such training was 
not available in seven countries, and 11 countries provided 
no information on the availability of this measure. 
(18) It was possible to add up to two additional measures under ‘other’. However, only one country made use of this option.





and testing on 




Initiation of opioid 
substitution treatment













Figure 5:  National priorities in the prevention of infectious 
diseases among drug users in prison settings
(1) Including counselling.
(2) Prison treatment centres, specialised prison treatment wards.
Sources: Reitox national focal points.
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Needle and syringe programmes
Needle and syringe programmes exist in prisons in five EU 
Member States (Germany, Spain, Luxembourg, Portugal, 
Romania), although varying levels of provision are reported. 
While the capacity for syringe provision in the programme 
operating in the main prison in Luxembourg is considered to 
be sufficient to meet injecting prisoners’ needs, and the 
majority of prisoners in Spain (19) who need syringes can 
obtain them from programmes running in 41 prisons, access 
to the programme in Romania is described as low, with just 
83 prisoners taking part during 2011 in the programmes 
established in 10 prisons. In Portugal, where a legal basis 
for prison needle and syringe programmes has existed since 
2007, a study cited in the Reitox national report shows that 
the two programmes established in 2008 were not accepted 
by the inmates, who feared discrimination (20). In Germany, 
only one site from a wider model project on prison syringe 
exchange, conducted until the end of 1998, remains in 
existence. In the women’s prison Berlin Lichtenberg, 
prisoners can anonymously obtain sterile syringes at vending 
machines. 
Although the introduction of needle and syringe 
programmes in prisons is recommended by international 
organisations (UNODC, 2012), and expert groups in several 
European countries have considered the measure (e.g. 
France, Hungary, Austria, United Kingdom, Norway), they 
face strong opposition, as they are often perceived as 
contradictory to the goal of a drug-free prison. Several 
countries provide disinfectants as an alternative. In 
Denmark, France, Lithuania, Austria, Finland, the United 
Kingdom and Norway, chlorine rinse fluid or other 
disinfectants are made available. While laboratory studies 
have shown efficacy of using bleach to eliminate HIV 
(Abdala et al., 2001), it has been doubted whether this 
measure is sufficiently safe under ‘real-life’ conditions in 
prison. In three countries (Belgium, Hungary, Netherlands), 
recent studies showing a low level of injecting drug use 
among the prisoner population are cited as the reason that 
needle and syringe programmes are not prioritised. 
Treatment of hepatitis C in prison
As injecting drug users constitute a sizeable proportion of 
the population infected with HCV, and many of them can be 
reached in prisons, this setting provides an opportunity for 
treatment to reduce the national burden of hepatitis C and 
eliminate prison-to-community spread of the disease. The 
provision of treatment represents, however, a considerable 
challenge to national prison systems, not only because of its 
high costs, but also because it requires a multidisciplinary 
approach with collaboration between experts in infectious 
diseases and drug dependence treatment. 
Hepatitis C testing is not always offered to or requested by 
prisoners, and as the infection is often asymptomatic, many 
do not know if they are infected. In some cases, the high 
costs of subsequent treatment may determine whether the 
prison health system offers the test. 
A growing body of evidence from European prisons shows 
that hepatitis C treatment is feasible and effective in these 
settings. Currently, the state-of-art treatment for this infection 
is the use of pegylated interferon and ribavirin, but new 
drugs are under development. While a number of logistical 
and medical challenges (e.g. addressing the side-effects of 
interferon; treatment of co-infections and psychiatric 
disorders) exist, a prison stay can create an opportunity for 
treatment. Tan et al. (2008) investigated the cost-
effectiveness of hepatitis C treatment with pegylated 
interferon and ribavirin in the US prison population, and 
concluded that the treatment results in both improved quality 
of life and cost savings for almost all segments of the inmate 
population. 
The available data on the provision of hepatitis C treatment 
in prison, although scarce, seem to indicate that only a 
small proportion of those who have contracted the infection 
are treated. In the Netherlands, in order to avoid 
interruption of treatment on release, only prisoners 
sentenced for more than 6 months are given the option of 
starting treatment. Short-term prisoners are referred to 
treatment in the community. A study among prison doctors 
in Germany found that 6 % of prisoners infected with HCV 
received treatment. In Hungary, 48 prisoners started 
antiviral hepatitis C treatment in 2010, and in the Czech 
Republic 56 cases were registered. In France, a recent 
study reported that nearly half of HCV-positive inmates had 
received a treatment (Semaille et al., 2011), while an earlier 
retrospective mail survey among French prisoners and a 
retrospective prison study reported hepatitis C treatment 
uptake in the range of 14 % (Remy, 2006) and 23 % (Allen 
et al., 2003) of HCV-positive prisoners. A prospective study 
of 268 HCV-positive prisoners in Luxembourg showed a 
hepatitis C treatment uptake of 32 % among this population 
(Strock et al., 2009). 
(19) Including 10 prisons in Catalonia.
(20)  The programme was developed in the framework of a pilot project, and was implemented in the prisons of Lisbon and Paços de Ferreira between July 
2008 and March 2009.
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Release preparation and throughcare
Most social care and rehabilitation strategies and 
procedures for those leaving prison are directed at the 
general prisoner population. However, some pre-release 
measures are particularly important for those who use or 
have used drugs. 
Of special importance for drug users during the phase 
immediately preceding prison release — but ideally a 
process throughout the whole sentence — is cooperation 
between services inside the prison with health and social 
services outside, to ensure a seamless transition into 
community treatment. The term ‘throughcare’ refers to 
arrangements for managing the continuity of care before, 
during and immediately after custody (21). Throughcare and 
referral to external service providers is a general duty of 
prison or probation services, and can be crucial in 
preventing relapse (Prison Drug Treatment Strategy Review 
Group, 2010). In countries where prison and community 
health services operate ‘under the same roof’, throughcare 
between the two settings is easier to achieve, as integrated 
programmes operating inside prison can establish links into 
the community before the prisoner leaves the institution. In 
some prison systems, pre-release units have been set up to 
facilitate such referrals and to allow a smoother transition. 
One example is the central intake units in Flemish prisons, 
funded by the Ministry of Justice and run by external drug 
workers whose task is healthcare provision. Similarly, the 
‘exit unit’ in the Portuguese prison system is a residential 
facility aimed at those who have completed drug treatment 
and are entitled to less restrictive conditions, including visits 
to the outside in an open prison regime, thereby allowing 
the prisoners to organise their future housing and 
employment before release. 
A number of interventions targeting opioid users have been 
recommended to reduce the risk of a fatal overdose in the 
period shortly following prison release (22). They include 
pre-release counselling on overdose risk and training in first 
aid and overdose management; optimising referral to 
achieve continuity of drug treatment between prison and 
community; and the distribution of naloxone among opioid 
users leaving prison. Reliable data about the availability of 
pre-release measures are scarce. However, provision of 
naloxone on prison release is available across the England, 
Scotland and Wales prison estates, but is not reported from 
other countries. Examples of good practice for community-
based organisations have been collected in the ‘Through the 
gate’ scheme in Wales and include ‘in-reach’, prison gate 
pick-up, assertive outreach, local networking and enhanced 
engagement with support services. 
Although the European Prison Rules specify that prisoners 
should be offered a medical examination as close as 
possible to the time of release, a routine ‘exit’ health 
examination does not seem to be common in Europe: only 
reports from Croatia and Slovakia mentioned this as a 
statutory service in their prison systems.
(21) A throughcare toolkit was produced under the EU-funded research project ‘Throughcare for prisoners with problematic drug use’ and is available online.
(22) See the section ‘Mortality after prison release’.
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The current EU drugs action plan calls on Member States to 
increase the use of effective alternatives to incarceration of 
drug-using offenders. Despite evidence of an increased 
interest in providing ‘alternatives to prison’, many people 
with drug problems continue to pass through Europe’s prison 
systems every year. Drawing on the available information, 
this Selected issue has presented an up-to-date overview of 
both the drug situation and health and social responses to 
drug-related problems in European prisons.
All evidence points to the fact that, when compared with 
the general population, prisoners as a group are 
particularly disadvantaged and marginalised. Most 
prisoners have limited education and low socioeconomic 
status, and poverty, violence and crime are common 
experiences in prisoners’ lives. Incarcerated non-nationals, 
who account for more than 20 % of all prisoners in 13 EU 
Member States (Table 3.2 in Aebi and Del Grande, 2012), 
are among the most vulnerable prisoners. Similarly, women 
prisoners, although accounting for only a minority of prison 
inmates, are a group with complex health and social 
needs. Surveys on prison health also document elevated 
levels of physical and mental health problems among 
prisoners, often coupled with chronic and entrenched drug 
use problems. 
Drug-using prisoners: an 
opportunity for intervention
Studies confirm that both drug use and drug use-related 
health problems are far more common among prisoners than 
in the general population. Lifetime prevalence of substance 
use, including illicit drug use, is reported to be very high 
among prisoners, with levels of up to 80 % for tobacco and 
cannabis use and up to 50 % for cocaine, heroin and 
amphetamines consumption. Although many prisoners stop 
or reduce their drug use when they enter prison, some 
continue to use drugs, sometimes switching to different 
substances or starting an additional drug while incarcerated. 
There is also evidence that some prisoners, who have never 
used drugs before, have their debut with illicit drugs while in 
prison. 
In Europe, drug users represent a large proportion of the 
prison populations and, for some, periods of incarceration 
may offer an opportunity to reduce their drug use and 
engage with services. In this respect, imprisonment may be 
viewed as a chance to make contact with and provide 
treatment for a particular group of ‘hard to reach’ problem 
drug users, leading to their better health and also reducing 
risks to the community on their release. The current EU drugs 
action plan prioritises the further development and 
improvement of drug-related assistance for detainees, 
including better access to drug-related prevention, treatment, 
harm reduction and rehabilitation services, of a standard 
that is comparable to the services provided in the 
community. Opportunities in this area have been increasing, 
as many countries have scaled up their provision of 
interventions within prisons, in particular offering more 
substitution treatment slots for those who are opioid-
dependent. However, in spite of progress in many European 
countries, the extent and quality of prison health service 
delivery still varies widely between countries, and rarely do 
prison health services offer an equivalent and comparable 
standard of care to that provided to the wider community. 
A number of recent European and international studies have 
identified a very high risk of drug overdose mortality among 
newly released prisoners owing to relapse into heroin use 
alongside reduced tolerance. The time around release is a 
particularly important period for preventive interventions, 
such as pre-release counselling, as well as for ensuring 
continuity of care on release in order to keep vulnerable 
individuals in contact with services and reduce drug-related 
deaths. 
Prisoners’ health: complex service needs
Drug users among prisoner populations often suffer from 
multiple mental health and somatic co-morbidities, and 
require specialised services to treat both their drug use and 
health problems. Mental health problems are very common 
among prisoners, and may be associated with the high 
levels of self-harm that are documented in prison, where 
suicide is the leading cause of death. A particular concern 
for this group is the transmission of infectious diseases such 
Conclusions
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as hepatitis C, tuberculosis and HIV/AIDS in prisons. 
Drug-using prisoners often share needles and other 
paraphernalia, increasing their exposure to infectious 
diseases. Poor living conditions, such as overcrowding and 
poor hygiene, aggravate the risk of infections and decrease 
prison’s safety. As prisoners move into and out of the 
general community, failure to maintain healthy living 
conditions in prison will impact negatively on the health of 
the community in general. More positively, imprisonment 
may provide an opportunity to intervene and provide 
treatment of infectious diseases, including hepatitis C, 
leading to improved prisoner health and also reducing risks 
to the community on their release.
Data limitations
The information available on drug use and responses in 
prison settings has a number of methodological limitations, 
which relate to both the nature of the subject (drug use and 
prison) and the lack of standardisation in data collection 
tools within and between countries. Data collection and 
research within prison settings are particularly affected by 
biases associated with self-selection, self-reporting and 
clustering. There are threats to validity linked to the 
sensitiveness of the topic (illicit drug use) and of the setting 
of the study (prison). In the prison setting, ethical aspects 
are especially important when collecting data, in particular 
with regard to confidentiality, anonymity and data 
protection issues. The use of relevant anonymised data 
from individual health records would be another option, 
but clear policies regarding confidentiality and data 
protection are needed when such data are collated at a 
central level. 
This report documents the progress that has been achieved 
in drugs service provision in prisons with regard to the use 
of evidence-based approaches. However, a number of 
serious shortcomings remain. At the European level there, is 
a lack of harmonisation of data collection: methodological 
differences can be found with regard to types of study, 
sampling methods, target populations and variables studied. 
These differences make it very difficult to draw comparisons 
between countries, and limit the possibilities for presenting a 
complete and comprehensive European picture of problems 
related to drug use in prison as well as an objective 
assessment of the need for and provision of drug-related 
health responses in prisons. 
Data monitoring on drugs and prison in 
Europe: a need for common standards
This review has demonstrated that prison health service 
delivery varies widely between countries, and that in many 
cases the evaluation and monitoring of drug-related health 
services are rare and do not follow the same standards. 
Under the last EU drugs action plan, which is coming to an 
end in 2012, Member States are called to endorse 
indicators to monitor drug use, drug-related health problems 
and drug services in prison on the basis of a methodological 
framework. As a complement to the healthcare-related 
recommendations of the European Prison Rules, an EU 
monitoring framework of drug-related prison health would 
address national drug-related prison health policies; data 
collection and monitoring infrastructures as well as quality 
standards and guidelines for drug-related services and 
interventions in prisons. A corresponding set of indicators on 
service needs (drug use, risk behaviours, health 
consequences) and service provision would facilitate the 
collection of objective, reliable and comparable data on 
drug-related prison health in Europe.
Closing the gap between prison and 
community: equivalence of care
There is wide recognition among EU policymakers of the need 
to harmonise practice and quality of health and social care 
services between community and prisons, and to respond 
better to the more severe health situation of the prisoner 
population. Progress has been made in some European 
countries, although the gap between prison and community in 
terms of levels and quality of health services available to 
prisoners still remains wide. Prison healthcare has, in the past 
decade, increasingly been recognised as part of public 
healthcare, and, consequently, several countries have 
transferred the responsibility for the healthcare of prisoners 
from justice ministries or the prison administration to health 
ministries. Others have drawn up specific drug and health 
strategies or regulations for the prison setting. A strong 
argument exists that any successful approach to improving 
prison health in the future must recognise the importance of 
including harm reduction and drug treatment services 
alongside, and integrated with, generic somatic and mental 
healthcare responses, a functioning throughcare mechanism 
in the community and substantial efforts to improve the 
reintegration of former prisoners. 
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